Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Thursday, June 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aclaris Therapeutics, Inc. will present at the H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025. The presentation will be accessible via a live and archived webcast on their website. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Price reaction · baseline $1.56 (2025-06-26 close) · hit after-hours · 2 other ACRS headline(s) in the window, move may be shared
day 0 close
-5.8%
day 1 · peak
-9%
day 3
-7.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris is actively participating in a significant industry conference.
  • The company is focused on developing novel treatments for immuno-inflammatory diseases.
  • Aclaris has a robust R&D engine supporting its product pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT.
A live and archived webcast of the presentation will be accessible on the Events page ofhttps://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris onX(formerly Twitter) at @AclarisTx and onLinkedIn.

Aclaris Therapeutics Contact:

Will RobertsSenior Vice PresidentCorporate Communications and Investor Relations(484) 329-2125wroberts@aclaristx.com

Frequently Asked Questions

When will Aclaris present at the conference?

Aclaris will present on June 30, 2025, at 11:30 AM EDT.

Where can I access the presentation?

The presentation will be available on Aclaris' Events page and archived for 30 days.

What is Aclaris Therapeutics focused on?

Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases.

Who can I contact for more information?

Contact Will Roberts, Senior VP of Corporate Communications, at Aclaris.

ShareAdd on Google
Tags: ACRS Viatris Investor Conferences Healthcare Aclaris Therapeutics H.C. Wainwright immuno-inflammatory diseases biopharmaceutical clinical-stage
Last updated: Jun 26, 2025

Biotech snapshot

Cash runway
$171M liquidity · $7M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ATI-045Phase 2
Atopic Dermatitis →

Catalyst track record

+181%
best trade around ACRS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACRS.

See every catalyst's timing & PoA →